

## Special Issue

# The Challenges and Therapeutic Prospects in Autoimmune Diseases

### Message from the Guest Editors

Autoimmune diseases are rare diseases with single-organ or multisystemic impact that can cause a lot of damage. Moreover, being rare diseases, most of the time there is no valid evidence concerning their treatment. Frequently, there is no accurate test for their diagnosis either, and the diagnosis is made using far from perfect criteria, or by exclusion. The treatment landscape of this kind of disease has evolved during the last 25 years, as new knowledge and new technologies have emerged that led to the appearance of new drug classes. Nevertheless, as the treatment of autoimmune diseases almost always involves immunosuppressive drugs, patients may easily contract infections, and sometimes it is hard to differentiate the infection from a disease flare-up. This raises other problems with respect to the treatment of such patients. These are some of the challenges of autoimmune diseases. This Special Issue welcomes original research papers, systematic reviews, or narrative reviews addressing fundamental, translational, and clinical aspects from this domain.

### Guest Editors

Prof. Dr. Cristian Baicus

Dr. Camelia Badea

Dr. Razvan Adrian Ionescu

### Deadline for manuscript submissions

closed (25 March 2024)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/166670](https://mdpi.com/si/166670)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).